Citigroup Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock (NASDAQ:SRRK) had its price objective raised by analysts at Citigroup from $55.00 to $58.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective would suggest a potential upside of 26.69% from the stock’s previous close.

A number of other analysts have also weighed in on the stock. Piper Sandler upped their price objective on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday. UBS Group started coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday. Finally, BMO Capital Markets boosted their price objective on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $54.14.

Scholar Rock Trading Up 3.3%

SRRK traded up $1.47 during trading on Wednesday, hitting $45.78. 2,710,176 shares of the stock were exchanged, compared to its average volume of 1,067,223. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a 50 day simple moving average of $45.29 and a 200 day simple moving average of $39.08. The firm has a market cap of $4.67 billion, a price-to-earnings ratio of -14.53 and a beta of 0.70. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $49.82.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period in the previous year, the firm earned ($0.64) earnings per share. As a group, equities analysts expect that Scholar Rock will post -2.42 EPS for the current year.

Insiders Place Their Bets

In related news, General Counsel Junlin Ho sold 9,580 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $445,757.40. Following the transaction, the general counsel directly owned 241,545 shares of the company’s stock, valued at $11,239,088.85. This represents a 3.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Mo Qatanani sold 8,484 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $47.07, for a total value of $399,341.88. Following the completion of the sale, the insider directly owned 98,445 shares of the company’s stock, valued at approximately $4,633,806.15. This represents a 7.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 344,932 shares of company stock worth $15,371,225. 13.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds have recently modified their holdings of SRRK. Three Seasons Wealth LLC boosted its stake in Scholar Rock by 2.1% in the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock worth $483,000 after purchasing an additional 222 shares in the last quarter. IFP Advisors Inc increased its stake in Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Scholar Rock by 7.9% during the third quarter. Principal Financial Group Inc. now owns 6,214 shares of the company’s stock worth $231,000 after buying an additional 456 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of Scholar Rock by 0.9% during the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after buying an additional 577 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock News Summary

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Piper Sandler raised its price target to $58 and initiated/maintained an “overweight” view, implying ~31.5% upside from recent levels — a clear catalyst for buying interest. We are incrementally positive on Scholar Rock (SRRK) Shares; PT Raised at Piper Sandler
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $58 price target, reinforcing analyst optimism and supporting momentum. HC Wainwright Reaffirms Buy; $58 PT
• Positive Sentiment: Q4 2025 results beat consensus — reported EPS/loss was better than expectations (company reported a smaller-than-expected loss), which traders interpret as operational progress ahead of key clinical milestones. Scholar Rock Q4 2025 Press Release / Financial Results
• Neutral Sentiment: Multiple transcripts and call coverage (Seeking Alpha, InsiderMonkey, Yahoo Finance) are available for the Q4 earnings call — useful for investors digging into management commentary on pipelines, cash runway and upcoming catalysts but not a direct immediate catalyst by itself. Q4 2025 Earnings Call Transcript (InsiderMonkey)
• Negative Sentiment: The company acknowledged a correcting press release: while the quarter beat estimates, net loss widened year‑over‑year (reported net loss per share larger than the year‑ago quarter), which could temper enthusiasm until clinical/financial trends become clearer. Correcting and Replacing: Q4 & Full Year 2025 Financial Results

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).